Supporting commercialization of Nanoprotec® in Europe
Swave develops holographic eXtended reality technology to make virtual reality practically indistinguishable from the real world.
Spica is pioneering Macrophage-Subset targeted therapies
Passing the torch – A new chapter at Blue Foot
eyeo develops breakthrough color-splitting photonics for ultra-compact, high-performance imaging
VIB launches new Agtech spin-off Rainbow Crops to develop climate-resilient crop varieties
Commercializing Nanoprotec® for ETEC protection in piglets in Europe
moveUP develops personalized remote digital care for patients undergoing surgery and other interventions.
Aloxy offers reliable IIot solutions tailored to the needs of the process industry.
Pleevi makes workplace charging smarter, greener and more cost-efficient
A seasoned Chief Executive, with over 20 years of distinguished leadership in medical biotechnology
QustomDot is developing cadmium-free quantum dots that are stable enough for advanced applications.
Cascador Health bridges the gap between data sources and the users of healthcare data.
Obulytix develops the next generation of enzyme-based antibiotics inspired by nature.
Strong investor syndicate and renowned board of scientific experts demonstrate the high potential of Tanai’s innovative approach
MRM Health is developing a novel type of therapeutics based on beneficial intestinal bacteria.
Weavely develops a no-code platform that generates interactive content from digital designs.
Blue Foot provides water-intensive industries with the technology to reuse water.
Veterinary therapeutics company Animab welcomes new Chairman of the Board.
Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors
AmphiStar secures €6 million to launch eco-friendly and cost-effective biosurfactants derived from waste
VoxelSensors is developing ultra-low power and ultra-low latency 3D perception sensors for Extended Reality.
New VIB spinoff Tanai Therapeutics develops first-in-class therapeutics for obesity
Obulytix is developing a revolutionary solution for antibiotic resistance
ABSCINT is developing single-domain antibodies for disease diagnosis through imaging.
Developing new technology for accurate drug concentrations in blood.
Aphea.Bio is developing the next generation of agricultural biologicals.
Qbic III increases capital to 88.5 million euros to invest in spin-off companies of Belgian world-renowned knowledge institutions.
Qbic is looking to strengthen its team with an Investment Analyst
Indigo is developing an implantable sensor that allows to continuously measure glucose and other metabolites for up to two years.
Animab develops antibodies to tackle gastrointestinal pathogens in livestock.
Weave.ly is developing a pioneering no-code platform that allows for partial automation of the software development process.
THERAtRAME develops and positions new therapeutics targeting tRNA epitranscriptomics in cancer.
Qbic announces first close of new fund at € 49 million to invest in spin-offs from world-class knowledge partners.
EyeD Pharma is developing micro-implants for drug release over a prolonged period of time.
Biogazelle develops and deploys high-end digital PCR, quantitative PCR and RNASeq assays.
Trince developed a new transfection technology based on a combination of laser light and photothermal nanoparticles.
Molecubes builds preclinical imaging cubes, allowing SPECT, PET and CT imaging in almost any lab space.
PharmaFluidics developed a complementary range of reversed-phase chromatography columns for systems biology and biopharma applications.
Sentea leverages silicon photonics to develop a cost-effective fiber optic sensor interrogator.
CrowdScan provides accurate and privacy-friendly crowd measurement data.
moveUP develops data-driven personalized remote digital care for patients undergoing surgery and other interventions.
ABSCINT focuses on diagnostics based on single domain antibodies.
Indigo is pioneering an invisible glucose sensor for people living with diabetes.
Accelleran is a global leader in 4G/5G Cloud-Native OpenRAN platforms.
_b.jpg)
%20-%20600%20400.jpg)
%20600%20400.jpg)
